linjc16/ctgov huggingface dataset:
Endobronchial Ultrasound Guided Transbronchial Needle Aspiration Performed Under General Anesthesia Versus Moderate Sedation

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine if there are any differences in yield or safety of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) (a type of bronchoscopy with biopsy) performed under general anesthesia versus moderate sedation.

Official Title
-----------------
Randomized Controlled Trial Comparing Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) Performed Under General Anesthesia Versus Conscious Sedation

Conditions
-----------------
Mediastinal Lymphadenopathies, Mediastinal Masses, Hilar Lymphadenopathies

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients over the age of 18, evaluated by pulmonary physician that require EBUS TBNA for sampling of hilar and/or mediastinal lymphadenopathies or masses Patients should be considered eligible to undergo either CS or GA, without contraindications for either one of them, based on the assessment by the pulmonologist who will perform EBUS-TBNA Exclusion Criteria: Pregnancy or breastfeeding women Patients deemed poor candidates for general anesthesia by the evaluating physician (e.g., severe coronary artery disease, COPD with FEV1 < 1 liter, uncontrolled hypertension, increased intracranial pressure, reaction to anesthetics) Previous reaction to medications routinely used in conscious sedation Patients with history of intolerance to either general anesthesia or conscious sedation Dementia or other severe cognitive impairment causing inability to understand or consent to the procedure and study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| General Anesthesia<br>Patients will receive Total Intravenous Anesthesia (TIVA) with a combination of Propofol, Ketamine and neuromuscular blockade by anesthesia. Either an LMA or an ETT will be used to secure airway. | |
| Moderate Sedation<br>Patients will receive moderate sedation given by the physician performing EBUS with a combination of Versed and Fentanyl per hospital protocol. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic Yield |  | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complications rate |  | 24 months | 
| Time to recovery from anesthesia |  | 24 months | 
| Tolerance to procedure |  | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
EBUS, mediastinal lymph nodes, mediastinal masses, anesthesia, moderate sedation
Transcranial Direct Current Stimulation (TDCS) for Facilitating Swallowing Improvement After an Acute Unilateral Hemispheric Stroke

Study Overview
=================
Brief Summary
-----------------
The purpose of the research study is to investigate the effect of a brain stimulation technique called Transcranial Direct Current Stimulation (TDCS) in improving swallowing functions in subjects who develop dysphagia after a unilateral hemispheric infarction.

Official Title
-----------------
Pilot Study of Transcranial Direct Current Stimulation for Facilitating Swallowing Improvement After an Acute Unilateral Hemispheric Infarction

Conditions
-----------------
Dysphagia

Intervention / Treatment
-----------------
* Other: tDCS
* Other: Sham


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute ischemic stroke Between 24-168 hours after onset Moderate to severe dysphagia based on swallowing assessment Exclusion Criteria: Preexisting swallowing impairment Intracerebral hemorrhage Pacemaker of other electrically sensitive device

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: tDCS<br>tDCS will provide an increase in cortical excitability. Patients will be randomized to receive tDCS or sham stimulation. | Other: tDCS<br>* tDCS will lead to an increase in cortical excitability<br>|
| Placebo Comparator: sham<br>Sham stimulation will provide identical subjective sensation as anodal tDCS. | Other: Sham<br>* Sham will provide identical subjective sensation as tDCS<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dysphagia Outcome and Severity Scale Score (DOSS) | DOSS is a validated swallowing assessment scoring system that will rate the severity of dysphagia. It will be performed by a speech and swallow pathologist. | 5 days after study enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of seizure | Number of patient having seizures during the 5 sessions of stimulation in either groups will be tabulated and compared. | 5 days after study enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
swallowing, stroke
A Study of Capecitabine (Xeloda) in Participants With Locally Advanced or Metastatic Pancreatic Cancer

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the efficacy and safety of oral capecitabine plus intravenous (IV) gemcitabine in participants with locally advanced or metastatic pancreatic cancer. The anticipated time on study treatment is 3 to 12 months, and the target sample size is 56 individuals.

Official Title
-----------------
An Open-label, Phase II Study of Capecitabine Plus Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Conditions
-----------------
Pancreatic Cancer

Intervention / Treatment
-----------------
* Drug: Capecitabine
* Drug: Gemcitabine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult participants 18 to 75 years of age Locally advanced or metastatic pancreatic cancer Exclusion Criteria: - Prior chemotherapy for pancreatic cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Capecitabine + Gemcitabine<br>Participants will receive oral capecitabine (830 milligrams per meter-squared [mg/m^2]) twice daily (BID) as intermittent treatment (Days 1 to 21 every 4 weeks [q4w]) along with IV infusion of gemcitabine (1000 mg/m^2) once weekly as intermittent treatment (4-week cycles of 3-week treatment period and 1-week rest period). | Drug: Capecitabine<br>* Capecitabine will be administered orally at 830 mg/m^2 BID (equivalent to a total daily dose of 1660 mg/m^2) as intermittent treatment (given days 1 to 21 q4w).<br>* Other names: Xeloda;Drug: Gemcitabine<br>* Gemcitabine will be administered at a dose of 1000 mg/m^2 once weekly via IV infusion as intermittent treatment (repeated 4-week cycles of 3 weeks treatment and 1 week rest).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall objective response rate |  | At the end of 6 cycles (24 weeks) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of response |  | Up to approximately 3.5 years | 
| Time to disease progression |  | Up to approximately 3.5 years | 
| Time to response |  | Up to approximately 3.5 years | 
| Time to treatment failure |  | Up to approximately 3.5 years | 
| Overall survival |  | Up to approximately 3.5 years | 
| Incidence of adverse events |  | Up to approximately 3.5 years |
Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine any adverse effects of PRO 542 after administration and to determine the anti-HIV effects of PRO 542 in the patient.

Detailed Description
-----------------
A 2 arm study involving a series of 3 triweekly doses of PRO 542. One arm will involve patients on a stable dose of anti-retroviral therapy and the other arm will consist of patients not receiving anti-retroviral therapy. Three patients will be enrolled in each arm followed by a safety evaluation. Following the safety evaluation, 3 more patients may be enrolled in each arm. After the first 12 patients, an additional 12 patients may be enrolled pending safety data.

Conditions
-----------------
HIV Infections, Acquired Immune Deficiency Syndrome

Intervention / Treatment
-----------------
* Drug: CD4-IgG2 (PRO 542)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed diagnosis of HIV Patients must be on a stable dose of acceptable anti-HIV therapy or receiving no anti-HIV therapy for at least four (4) weeks prior to the start of this study HIV-1 determination by RNA-PCR greater than or equal to 100,000 copies/ml CD4 count >50/cubic mm at screening Exclusion Criteria: Patients who have previously received PRO 542 Patients with active, significant infection (other than HIV) not controlled by antibiotics Pregnant or lactating women Patients with an estimated life expectancy of <3 months Patients currently receiving steroids or other immunosuppressive therapy or immunoglobulin therapy except for topical or inhaled steroids Patients with known allergy or hypersensitivity to PRO 542 or immunoglobulin preparations

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: CD4-IgG2 (PRO 542)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Treatment Experienced
Proper Nutrition And Its Relation To Oral Diseases In Covid -19 Era

Study Overview
=================
Brief Summary
-----------------
effect of proper diet and vitamins on the oral health and the regeneration of the taste and smell in Covid 19 patients

Detailed Description
-----------------
effect of proper diet and vitamins on the oral health ( bleeding gums, ulcers, bad breath) also the effect of proper diet on the regeneration of the taste and smell in Covid 19 patients A diet will be followed for 2 weeks then the progress will be evaluated by making another questionnaire

Official Title
-----------------
Proper Nutrition and Its Relationship to Oral Diseases in the Era of Corona

Conditions
-----------------
Diet, Healthy

Intervention / Treatment
-----------------
* Dietary Supplement: proper diet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Exclusion Criteria: chronic diseases

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| males from 20 to above 65 y<br>will be sub divided into 4 groups according to age sub group I from 20 - 35 sub group II from 36- 45 sub group III from 46- 65 sub group IV more than 65 | Dietary Supplement: proper diet<br>* diet containing all essential vitamins<br>|
| female from 20 to above 65 y<br>will be sub divided into 4 groups according to age will be sub divided into 4 groups according to age sub group I from 20 - 35 sub group II from 36- 45 sub group III from 46- 65 sub group IV more than 65 | Dietary Supplement: proper diet<br>* diet containing all essential vitamins<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| regeneration of taste | counting the fungiform papillae in 1cm x 1cm area of the tongue during the infection and after being cured | 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Proper Diet, Taste, Oral Health, Corona
The Role of Narrow Band Imaging Videobronchoscopy in Lung Cancer

Study Overview
=================
Brief Summary
-----------------
Narrow band imaging (NBI) videobronchoscopy is an optical technique in which filtered light enhances superficial neoplasm based on their neoangiogenic pattern. The objectives of this study investigate its better diagnostic yield in the assessment of lung cancer than conventional flexible bronchoscopy.

Detailed Description
-----------------
Inspection with high resolution endoscopy was followed by NBI. Detected lesions were biopsied. applied the system of shibuya et al. to analyze and classify vascular patterns by NBI into four categories (spiral and screw pattern, dotted pattern, tortuous pattern, avascular pattern) compared with the known diagnostic yield of conventional white light bronchoscopy, An equivalent or superior result will also significantly impact on patient care This technology could aid not only early-stage lung cancer diagnosis but also more accurate local staging of lung cancer.

Official Title
-----------------
The Diagnostic Yield of Narrow Band Imaging Videobronchoscopy in Lung Cancer

Conditions
-----------------
Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: endobronchial lesion on chest CT Exclusion Criteria: Age < 18 years old Inability to consent for the study Inability to tolerate bronchoscopy Active pulmonary infection (bronchitis, pneumonia) ST elevation or depression on ECG Prothrombin time prolongation(<70%) platelet <10,000

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| lung cancer<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| accuracy of NBI videobronchoscopic biopsy | Define and compare the sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratio and accuriacies for the diagnostic techniques for lung cancer. | 10-11 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| early cancer lesion detection rate using Shibuya descriptors | Define and compare the sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratio and accuriacies for the diagnostic techniques for early lung cancer. | 10-11 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
narrow band imaging, malignant lesion, lung cancer, NBI
Phase II Randomized Study of Stereotactic Radiosurgery Plus Fractionated Whole-Brain Radiotherapy Vs Fractionated Whole-Brain Radiotherapy Alone for Multiple Primary or Metastatic Brain Tumors

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Evaluate whether stereotactic radiosurgery provides local control at multiple sites in patients with primary or metastatic brain tumors, controlled systemic disease, and preserved neurologic function. II. Examine survival, clinical outcome, and local tumor imaging response in these patients.

Detailed Description
-----------------
PROTOCOL OUTLINE: This is a randomized study. Tumor size and number are confirmed prior to randomization. Patients are stratified by participating institution. Patients are randomly assigned to 1 of 2 treatment groups. One group is treated with fractionated whole-brain irradiation using megavoltage equipment. The second group receives stereotactic radiosurgery plus fractionated whole-brain radiotherapy. Stereotactic radiosurgery involves irradiation of all tumors to the margins on stereotactic computerized tomography or magnetic resonance imaging. Either treatment may be administered first; the second treatment begins within 1 month of the first. Concurrent anticonvulsants and steroids are allowed. Patients are followed for change in size and number of tumors at 1, 3, and 6 months; follow-up clinical exams are performed at least every 2 months.

Conditions
-----------------
Brain Neoplasms

Intervention / Treatment
-----------------
* Procedure: irradiation
* Procedure: radiosurgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Multiple newly diagnosed brain tumors Histologic confirmation of carcinoma at primary or metastatic site Tumors less than 25 mm mean diameter and more than 5 mm from optic chiasm No more than 4 tumors on magnetic resonance imaging Systemic disease controlled Neurologic function preserved Radiographic staging within 2 months of randomization required Performance status: Karnofsky 70%-100%

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: irradiation|nan|
|Procedure: radiosurgery|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adult brain tumor, brain tumor, childhood brain tumor, genetic condition, nervous tissue tumors, oncologic disorders, rare disease
Measurement of Recirculation During Venovenous Extracorporeal Membrane Oxygenation (VV ECMO)

Study Overview
=================
Brief Summary
-----------------
This study is to test the usefulness of ultrasound dilution recirculation measurements in patients receiving venovenous extracorporeal membrane oxygenation as therapy. The ultrasound dilution measurements determine the efficiency of support provided by venovenous extracorporeal membrane oxygenation. At the present time there are no other devices available to make recirculation measurements.

Detailed Description
-----------------
At the present time there are no devices available to measure recirculation in patients on venovenous extracorporeal membrane oxygenation. The study uses an external monitor, laptop computer, clamp on flowsensors and ultrasound dilution technology to measure blood flow. Measurements are made by injecting 0.5 - 1 ml/kg of sterile isotonic saline into the patient's extracorporeal circuit. The subject will be monitored throughout the measurements. The measurements will be coordinated with the regular care of the patient and their extracorporeal circuit.

Official Title
-----------------
Ultrasound Dilution Measurement of Recirculation During Venovenous Extracorporeal Membrane Oxygenation

Conditions
-----------------
Venovenous Extracorporeal Membrane Oxygenation, Recirculation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients between 0 and 21 years of age Patients receiving venovenous extracorporeal membrane oxygenation as treatment. Exclusion Criteria: Patients over 21 years of age Patients not receiving venovenous extracorporeal membrane oxygenation.

Ages Eligible for Study
-----------------
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recirculation measurements made in patients receiving venovenous extracorporeal membrane oxygenation. |  | Duration of venovenous extracorporeal membrane oxygenation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
recirculation, ultrasound dilution, venovenous extracorporeal membrane oxygenation